nach oben

Erschienen in:

01.02.2015 | Meta-Analysis

Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials

verfasst von: Bin Su, Hui Sheng, Manna Zhang, Le Bu, Peng Yang, Liang Li, Fei Li, Chunjun Sheng, Yuqi Han, Shen Qu, Jiying Wang

Erschienen in: Endocrine | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Traditional anti-diabetic drugs may have negative or positive effects on risk of bone fractures. Yet the relationship between the new class glucagon-like peptide-1 receptor agonists (GLP-1 RA) and risk of bone fractures has not been established. We performed a meta-analysis including randomized controlled trials (RCT) to study the risk of bone fractures associated with liraglutide or exenatide, compared to placebo or other active drugs. We searched MEDLINE, EMBASE, and clinical trial registration websites for published or unpublished RCTs comparing the effects of liraglutide or exenatide with comparators. Only studies with disclosed bone fracture data were included. Separate pooled analysis was performed for liraglutide or exenatide, respectively, by calculating Mantel–Haenszel odds ratio (MH-OR). 16 RCTs were identified including a total of 11,206 patients. Liraglutide treatment was associated with a significant reduced risk of incident bone fractures (MH-OR = 0.38, 95 % CI 0.17–0.87); however, exenatide treatment was associated with an elevated risk of incident bone fractures (MH-OR = 2.09, 95 % CI 1.03–4.21). Publication bias and heterogeneity between studies were not observed. Our study demonstrated a divergent risk of bone fractures associated with different GLP-1 RA treatments. The current findings need to be confirmed by future well-designed prospective or RCT studies.

Nur mit Berechtigung zugänglich

M. Janghorbani, R.M. Van Dam, W.C. Willett, F.B. Hu, Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture. Am. J. Epidemiol. 166(5), 495–505 (2007). doi:10.1093/aje/kwm106 CrossRefPubMed

C. Hamann, S. Kirschner, K.-P. Gunther, L.C. Hofbauer, Bone, sweet bone—osteoporotic fractures in diabetes mellitus. Nat. Rev. Endocrinol. 8(5), 297–305 (2012)CrossRefPubMed

L.C. Hofbauer, C.C. Brueck, S.K. Singh, H. Dobnig, Osteoporosis in patients with diabetes mellitus. J. Bone Miner. Res. 22(9), 1317–1328 (2007)CrossRefPubMed

M. Monami, B. Cresci, A. Colombini, L. Pala, D. Balzi et al., Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients A case-control study. Diabetes Care 31(2), 199–203 (2008)CrossRefPubMed

P. Vestergaard, L. Rejnmark, L. Mosekilde, Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48(7), 1292–1299 (2005)CrossRefPubMed

S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355(23), 2427–2443 (2006)CrossRefPubMed

C. Meier, M.E. Kraenzlin, M. Bodmer, S.S. Jick, H. Jick et al., Use of thiazolidinediones and fracture risk. Arch. Intern. Med. 168(8), 820–825 (2008). doi:10.1001/archinte.168.8.820 CrossRefPubMed

M. Monami, I. Dicembrini, A. Antenore, E. Mannucci, Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: a meta-analysis of randomized clinical trials. Diabetes Care 34(11), 2474–2476 (2011). doi:10.2337/dc11-1099 CrossRefPubMedCentralPubMed

R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman et al., Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28(5), 1092–1100 (2005)CrossRefPubMed

10.

T. Vilsboll, M. Zdravkovic, T. Le-Thi, T. Krarup, O. Schmitz et al., Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30(6), 1608–1610 (2007). doi:10.2337/dc06-2593 CrossRefPubMed

11.

T. Vilsboll, M. Christensen, A.E. Junker, F.K. Knop, L.L. Gluud, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344, d7771 (2012)CrossRefPubMedCentralPubMed

12.

B. Wang, J. Zhong, H. Lin, Z. Zhao, Z. Yan et al., Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes. Metab. 15(8), 737–749 (2013). doi:10.1111/dom.12085 CrossRefPubMed

13.

M. Monami, I. Dicembrini, C. Nardini, I. Fiordelli, E. Mannucci, Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 16(1), 38–47 (2013). doi:10.1111/dom.12175 CrossRefPubMed

14.

B. Gallwitz, Extra-pancreatic effects of incretin-based therapies. Endocrine (2014). doi:10.1007/s12020-014-0223-0 PubMed

15.

S.K. Majumdar, S.E. Inzucchi, Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 44(1), 47–58 (2013). doi:10.1007/s12020-013-9884-3 CrossRefPubMed

16.

C.B. Giorda, E. Nada, B. Tartaglino, Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine (2014). doi:10.1007/s12020-014-0179-0

17.

N. Mikhail, Effects of incretin-based therapy in patients with heart failure and myocardial infarction. Endocrine (2014). doi:10.1007/s12020-014-0175-4

18.

G. Mabilleau, A. Mieczkowska, D. Chappard, Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials. J Diabetes 6(3), 260–266 (2014). doi:10.1111/1753-0407.12102 CrossRefPubMed

19.

D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339(jul21 1), b2535-b2535 (2009). doi:10.1136/bmj.b2535

20.

A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J.M. Reynolds et al., Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin. Trials 17(1), 1–12 (1996). doi:10.1016/0197-2456(95)00134-4 CrossRefPubMed

21.

M.J. Bradburn, J.J. Deeks, J.A. Berlin, A. Russell Localio, Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat. Med. 26(1), 53–77 (2007). doi:10.1002/sim.2528 CrossRefPubMed

22.

M. Egger, G.D. Smith, M. Schneider, C. Minder, Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109), 629–634 (1997)CrossRefPubMedCentralPubMed

23.

C.B. Begg, M. Mazumdar, Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101 (1994)CrossRefPubMed

24.

M. Nauck, A. Frid, K. Hermansen, A.B. Thomsen, M. During et al., Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes. Metab. 15(3), 204–212 (2013). doi:10.1111/dom.12012 CrossRefPubMed

25.

A. Garber, R.R. Henry, R. Ratner, P. Hale, C.T. Chang et al., Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes. Metab. 13(4), 348–356 (2011). doi:10.1111/j.1463-1326.2010.01356.x CrossRefPubMedCentralPubMed

26.

J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683), 39–47 (2009). doi:10.1016/s0140-6736(09)60659-0 CrossRefPubMed

27.

R. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy et al., One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int. J. Clin. Pract. 65(4), 397–407 (2011). doi:10.1111/j.1742-1241.2011.02656.x CrossRefPubMedCentralPubMed

28.

M.E. Lean, R. Carraro, N. Finer, H. Hartvig, M.L. Lindegaard et al., Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) (2013). doi:10.1038/ijo.2013.149

29.

B. Charbonnel, H. Steinberg, E. Eymard, L. Xu, P. Thakkar et al., Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia 56(7), 1503–1511 (2013). doi:10.1007/s00125-013-2905-1 CrossRefPubMed

30.

J.B. Buse, M. Nauck, T. Forst, W.H.H. Sheu, S.K. Shenouda et al., Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381(9861), 117–124 (2013)CrossRefPubMed

31.

NCT00614120: Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes. http://www.clinicaltrials.gov/show/NCT00614120. Accessed 02/01 2014

32.

R.J. Heine, L.F. Van Gaal, D. Johns, M.J. Mihm, M.H. Widel et al., Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 143(8), 559–569 (2005)CrossRefPubMed

33.

M.A. Nauck, S. Duran, D. Kim, D. Johns, J. Northrup et al., A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50(2), 259–267 (2007). doi:10.1007/s00125-006-0510-2 CrossRefPubMed

34.

A. Gill, B.J. Hoogwerf, J. Burger, S. Bruce, L. Macconell et al., Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 9, 6 (2010). doi:10.1186/1475-2840-9-6 CrossRefPubMedCentralPubMed

35.

B. Gallwitz, M. Böhmer, T. Segiet, A. Mölle, K. Milek et al., Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 34(3), 604–606 (2011). doi:10.2337/dc10-1900 CrossRefPubMedCentralPubMed

36.

J.B. Buse, R.M. Bergenstal, L.C. Glass, C.R. Heilmann, M.S. Lewis et al., Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154(2), 103–112 (2011). doi:10.7326/0003-4819-154-2-201101180-00300 CrossRefPubMed

37.

B. Gallwitz, J. Guzman, F. Dotta, B. Guerci, R. Simo et al., Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 379(9833), 2270–2278 (2012). doi:10.1016/s0140-6736(12)60479-6 CrossRefPubMed

38.

N. Inagaki, Y. Atsumi, T. Oura, H. Saito, T. Imaoka, Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther 34(9), 1892–1908 e1891 (2012). doi:10.1016/j.clinthera.2012.07.007

39.

NCT00960661: A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes http://www.clinicaltrials.gov/ct2/show/NCT00960661. Accessed 02/01 2014

40.

C. Yamada, Y. Yamada, K. Tsukiyama, K. Yamada, N. Udagawa et al., The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption. Endocrinology 149(2), 574–579 (2008). doi:10.1210/en.2007-1292 CrossRefPubMed

41.

B. Nuche-Berenguer, P. Moreno, S. Portal-Nuñez, S. Dapía, P. Esbrit, et al., Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept 159(1–3), 61–66 (2010). doi:http://dx.doi.org/10.1016/j.regpep.2009.06.010

42.

G. Mabilleau, A. Mieczkowska, N. Irwin, P.R. Flatt, D. Chappard, Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor. J. Endocrinol. 219(1), 59–68 (2013). doi:10.1530/joe-13-0146 CrossRefPubMed

43.

M. Monami, N. Marchionni, E. Mannucci, Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur. J. Endocrinol. 160(6), 909–917 (2009). doi:10.1530/eje-09-0101 CrossRefPubMed

44.

M.J. Jespersen, F.K. Knop, M. Christensen, GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert. Opin. Drug. Met. 9(1), 17–29 (2013). doi:10.1517/17425255.2013.731394 CrossRef

45.

Y.M. Cui, X.H. Guo, D.M. Zhang, L.S. Tham, C.C. Tang et al., Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus. J Diabetes 5(2), 127–135 (2013). doi:10.1111/1753-0407.12020 CrossRefPubMed

46.

M. Malm-Erjefält, I. Bjørnsdottir, J. Vanggaard, H. Helleberg, U. Larsen et al., Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase iv and neutral endopeptidase. Drug Metab. Dispos. 38(11), 1944–1953 (2010). doi:10.1124/dmd.110.034066 CrossRefPubMed

47.

J.B. Buse, A. Garber, J. Rosenstock, W.E. Schmidt, J.H. Brett et al., Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J. Clin. Endocrinol. Metab. 96(6), 1695–1702 (2011). doi:10.1210/jc.2010-2822 CrossRefPubMed

48.

J.A. Langlois, M.E. Mussolino, M. Visser, A.C. Looker, T. Harris et al., Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study. Osteoporos. Int. 12(9), 763–768 (2001). doi:10.1007/s001980170053 CrossRefPubMed

49.

L. Oei, M.C. Zillikens, A. Dehghan, G.H.S. Buitendijk, M.C. Castaño-Betancourt et al., High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study. Diabetes Care 36(6), 1619–1628 (2013). doi:10.2337/dc12-1188 CrossRefPubMedCentralPubMed

50.

S.S. Johnston, C. Conner, M. Aagren, K. Ruiz, J. Bouchard, Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes. Metab. 14(7), 634–643 (2012). doi:10.1111/j.1463-1326.2012.01583.x CrossRefPubMed

51.

A. Montagnani, S. Gonnelli, Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes. Metab. 15(9), 784–791 (2013). doi:10.1111/dom.12077 CrossRefPubMed

Titel: Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials
verfasst von: Bin Su
Hui Sheng
Manna Zhang
Le Bu
Peng Yang
Liang Li
Fei Li
Chunjun Sheng
Yuqi Han
Shen Qu
Jiying Wang
Publikationsdatum: 01.02.2015
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-014-0361-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

The effect of oral contraceptive different patterns of use on circulating IGF-1 and bone mineral density in healthy premenopausal women

High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves’ disease for 12 months

GH and the cardiovascular system: an update on a topic at heart

Increased low-density lipoprotein cholesterol level is associated with non-vertebral fractures in postmenopausal women

High-normal 2 h glucose is associated with defects of insulin secretion and predispose to diabetes in Chinese adults